AstraZeneca Pioneers U.K. Program Of Investigator-Led Studies For Novel Cancer Drug Combinations
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca is the first company to enter into a research agreement with a new alliance, formed by academia, the charity Cancer Research UK and the pharmaceutical industry, that aims to accelerate development of new anticancer combination therapies.